Celecoxib Nanoformulations with Enhanced Solubility, Dissolution Rate, and Oral Bioavailability: Experimental Approaches over In Vitro/In Vivo Evaluation.

Arslan, Aslihan; Yet, Barbaros; Nemutlu, Emirhan; Akdag Çayli, Yagmur; Eroglu, Hakan; Öner, Levent

Arslan, Aslihan; Yet, Barbaros; Nemutlu, Emirhan; Akdag Çayli, Yagmur; Eroglu, Hakan; Öner, Levent.

Afiliación

Arslan A; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey.
Yet B; Department of Cognitive Science, Graduate School of Informatics, Middle East Technical University, 06800 Ankara, Turkey.
Nemutlu E; Department of Analytical Chemistry, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey.
Akdag Çayli Y; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey.
Eroglu H; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey.
Öner L; Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey.

Pharmaceutics ; 15(2)2023 Jan 20.

Article en En | MEDLINE | ID: mdl-36839685

Palabras clave

Bayesian optimization; black-box; celecoxib; central composite design; characterization; dry co-milling; intrinsic dissolution rate; pharmacokinetics; response surface methodology

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Pharmaceutics Año: 2023 Tipo del documento: Article País de afiliación: Turquía

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google